SUTRO BIOPHARMA INC
COM · CUSIP 869367102
Q3 2025 share counts are adjusted for a 1-for-10 stock split, so holders aren't shown as buying or selling because of it.
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $11.57.
Trends to Q4 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2019 | 65 |
| Q1 2020 | 61 |
| Q2 2020 | 81 |
| Q3 2020 | 87 |
| Q4 2020 | 135 |
| Q1 2021 | 139 |
| Q2 2021 | 125 |
| Q3 2021 | 121 |
| Q4 2021 | 118 |
| Q1 2022 | 115 |
| Q2 2022 | 116 |
| Q3 2022 | 113 |
| Q4 2022 | 120 |
| Q1 2023 | 117 |
| Q2 2023 | 121 |
| Q3 2023 | 110 |
| Q4 2023 | 115 |
| Q1 2024 | 118 |
| Q2 2024 | 120 |
| Q3 2024 | 131 |
| Q4 2024 | 124 |
| Q1 2025 | 114 |
| Q2 2025 | 102 |
| Q3 2025 | 88 |
| Q4 2025 | 7 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2024 | 69 | 49 |
| Q2 2024 | 77 | 47 |
| Q3 2024 | 71 | 42 |
| Q4 2024 | 55 | 66 |
| Q1 2025 | 54 | 58 |
| Q2 2025 | 53 | 66 |
| Q3 2025 | 29 | 57 |
| Q4 2025 | 3 | 81 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q1 2025 | $34.5k | $27.0k | 0.78 |
| Q2 2025 | $40.6k | $0 | 0.00 |
| Q3 2025 | $5.5k | $0 | 0.00 |
| Q4 2025 | $0 | $0 | — |
Biggest buyers
| Fortitude Family Office, LLC | New | +56 |
| Parallel Advisors, LLC | Added | +0 |
| Merck & Co., Inc. | Added | +0 |
Biggest sellers
| MONTANOVA CAPITAL, LLC | Sold out | -648.8k |
| Kynam Capital Management, LP | Sold out | -508.8k |
| MILLENNIUM MANAGEMENT LLC | Sold out | -452.4k |
| VANGUARD GROUP INC | Sold out | -368.3k |
| ACADIAN ASSET MANAGEMENT LLC | Sold out | -338.9k |
| Velan Capital Investment Management LP | Sold out | -312.0k |
| TANG CAPITAL MANAGEMENT LLC | Sold out | -282.9k |
| Vestal Point Capital, LP | Sold out | -260.0k |
| Eversept Partners, LP | Sold out | -229.1k |
| SAMSARA BIOCAPITAL, LLC | Sold out | -219.7k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Affinity Asset Advisors, LLC 13G · passive investor new · filed 2025-10-23 | 7.8% |
| MILLENNIUM MANAGEMENT LLC 13G · passive investor new · filed 2025-06-30 | 5.6% |
| Kynam Capital Management, LP 13G · institution -1.2 pts · filed 2026-05-15 | 5.3% |
Fell to 5% or below in the last year: SUVRETTA CAPITAL MANAGEMENT, LLC (0.0%, 2026-02-13)
Holders, Q4 2025
| Manager | Shares | Change |
|---|---|---|
| Merck & Co., Inc. 1.22% of their portfolio | 272.4k $3.2m | Added +0 |
| AJU IB Investment Co., Ltd. 0.89% of their portfolio | 17.5k $202.5k | Unchanged |
| Fortitude Family Office, LLC 0.00% of their portfolio | 56 $648 | New |
| Bogart Wealth, LLC 0.00% of their portfolio | 50 $579 | Unchanged |
| Parallel Advisors, LLC 0.00% of their portfolio | 47 $544 | Added +0 |
| EverSource Wealth Advisors, LLC 0.00% of their portfolio | 31 $359 | Reduced -14 |
| Essential Partners LLC 0.00% of their portfolio | 4 $46 | Reduced -17 |